Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 11:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 33,121 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo Clear all
Completed Phase 2 Interventional

Efficacy, Safety and Tolerability of DNK333 (25 and 100 mg Bid) in Women With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

NCT00699166
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
DNK333
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older · Female only
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
29
States / cities
Anniston, Alabama • Huntsville, Alabama • Northport, Alabama + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2008 · Synced Oct 31, 2026, 11:12 PM EDT
Completed Phase 3 Interventional

Clinical Trial in Males With BPH (Enlarged Prostate)

NCT00029822
View directory record Official record
Conditions
Urinary Retention, Prostatic Hyperplasia, Benign Prostatic Hypertrophy
Interventions
Alfuzosin (SL770499)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
55 Years and older · Male only
Enrollment
1,522 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
35
States / cities
Huntsville, Alabama • La Mesa, California • San Bernardino, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2008 · Synced Oct 31, 2026, 11:12 PM EDT
Completed Phase 2 Interventional

Safety and Tolerability Study of Larazotide Acetate in Celiac Disease Subjects

NCT00362856
View directory record Official record
Conditions
Celiac Disease
Interventions
larazotide acetate, Placebo
Drug
Lead sponsor
9 Meters Biopharma, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
9
States / cities
Scottsdale, Arizona • San Diego, California • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2017 · Synced Oct 31, 2026, 11:12 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate Cortisol Reserve in Response to Adrenocorticotropic Hormone (ACTH) Stimulation Test Following Baxdrostat Treatment Compared to Placebo in Participants With Uncontrolled Hypertension

NCT06336356
View directory record Official record
Conditions
Uncontrolled Hypertension
Interventions
Baxdrostat, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
10
States / cities
Phoenix, Arizona • Tempe, Arizona • Montclair, California + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 31, 2026, 11:12 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Phase I, Double-Blind,Placebo, MAD Study to Evaluate the Safety, Tolerability, PK, and PD of AMG 333 in Healthy Subjects and Migraine Subjects

NCT02132429
View directory record Official record
Conditions
Migraine
Interventions
AMG 333, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 1, 2015 · Synced Oct 31, 2026, 11:12 PM EDT
Completed Phase 4 Interventional

A Functional Outcomes Study With Atomoxetine-Hydrochloride and Placebo in Adults With Attention-Deficit/Hyperactivity Disorder

NCT00190931
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Atomoxetine Hydrochloride, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 49 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 24, 2006 · Synced Oct 31, 2026, 11:12 PM EDT
Terminated Phase 2 Interventional Results available

Effectiveness of Gabapentin on Chronic Irritability in Neurologically Impaired Children

NCT01675960
View directory record Official record
Conditions
Neurologically Impaired, Irritable Mood, Signs and Symptoms, Digestive, Sleeplessness, Chronic Pain
Interventions
Gabapentin, placebo
Drug
Lead sponsor
Gillette Children's Specialty Healthcare
Other
Eligibility
1 Month to 16 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 2, 2019 · Synced Oct 31, 2026, 11:12 PM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Nicotinamide Riboside for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Middle-aged and Older Adults

NCT03821623
View directory record Official record
Conditions
Hypertension, Aging
Interventions
Nicotinamide riboside, Placebo
Drug · Other
Lead sponsor
Douglas Seals
Other
Eligibility
50 Years and older
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2027
U.S. locations
1
States / cities
Boulder, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 31, 2026, 11:12 PM EDT
Completed Phase 2 Interventional Results available

Lovastatin in Treating Patients At High Risk of Melanoma

NCT00462280
View directory record Official record
Conditions
Precancerous Condition, Stage 0 Melanoma, Stage I Melanoma, Stage II Melanoma
Interventions
lovastatin, placebo, biopsy, laboratory biomarker analysis
Drug · Other · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
3
States / cities
Orange, California • Tampa, Florida • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 31, 2014 · Synced Oct 31, 2026, 11:12 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Risperidone ISM® in Patients With Acute Schizophrenia: Open Label Extension

NCT03870880
View directory record Official record
Conditions
Schizophrenia
Interventions
Risperidone ISM 75 mg, Risperidone ISM 100 mg
Drug
Lead sponsor
Rovi Pharmaceuticals Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
13
States / cities
Rogers, Arkansas • Garden Grove, California • Long Beach, California + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2022 · Synced Oct 31, 2026, 11:12 PM EDT
Completed Phase 2 Interventional Results available

GB001 in Adult Participants With Chronic Rhinosinusitis

NCT03956862
View directory record Official record
Conditions
Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP), Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Interventions
GB001, Placebo
Drug
Lead sponsor
GB001, Inc, a wholly owned subsidiary of Gossamer Bio, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
29
States / cities
Tucson, Arizona • Jonesboro, Arkansas • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2021 · Synced Oct 31, 2026, 11:12 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase Ib/2a Drug-drug Interaction Study of a Combination of 45mg Dextromethorphan With 105 mg Bupropion

NCT05976646
View directory record Official record
Conditions
Addiction, Opioid Use, Substance Use Disorders, Opioid Use Disorder
Interventions
Placebo, Auvelity
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 31, 2026, 11:12 PM EDT
Active, not recruiting Phase 2 Interventional

Novel α2-Antiplasmin Inactivation for Lysis of Intravascular Thrombi (NAIL-IT) Trial

NCT05408546
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
TS23, Placebo
Drug
Lead sponsor
Translational Sciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
13
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 31, 2026, 11:12 PM EDT
Terminated Phase 2 Interventional Results available

Safety, Tolerability and Efficacy Study of LiRIS® 400 mg in Women With Interstitial Cystitis

NCT01824303
View directory record Official record
Conditions
Interstitial Cystitis
Interventions
LiRIS 400 mg, LiRIS Placebo
Drug · Other
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
15
States / cities
Glendora, California • Daytona Beach, Florida • Kansas City, Kansas + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2016 · Synced Oct 31, 2026, 11:12 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Impact of Haskap Berries on Recovery From High Intensity Resistance Training

NCT07344727
View directory record Official record
Conditions
Inflammation, Oxidative Stress, Resistance Exercise, Recovery, Exercise Performance Recovery
Interventions
Haskap berry smoothie, Placebo Comparator
Dietary Supplement
Lead sponsor
Montana State University
Other
Eligibility
18 Years to 35 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Bozeman, Montana
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 31, 2026, 11:12 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

A Study Assessing Safety, Tolerability, and Efficacy of INNA-051 in Preventing Respiratory Illness Due to Viral Infections in Healthy Adults 18 to 45 Years of Age

NCT07222670
View directory record Official record
Conditions
Viral Respiratory Infection, Viral Respiratory Illnesses
Interventions
INNA-051, Placebo
Drug · Other
Lead sponsor
ENA Respiratory Pty Ltd
Industry
Eligibility
18 Years to 45 Years
Enrollment
1,100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
6
States / cities
Baltimore, Maryland • Bethesda, Maryland • College Park, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 31, 2026, 11:12 PM EDT
Completed Phase 1 Interventional

Efficacy of Provex CV Supplement to Reduce Inflammation Cytokines and Blood Pressure

NCT01106170
View directory record Official record
Conditions
Blood Pressure
Interventions
Provex CV, placebo
Drug · Other
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 14, 2015 · Synced Oct 31, 2026, 11:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Glucose and Motivation States

NCT07255183
View directory record Official record
Conditions
Motivation
Interventions
Exercise, Sugar Drink, Non-sugar beverage
Behavioral · Dietary Supplement
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 31, 2026, 11:12 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety/Tolerability of Grass MATA MPL

NCT00414141
View directory record Official record
Conditions
Type I Hypersensitivity
Interventions
Grass MATA MPL, Placebo
Biological
Lead sponsor
Allergy Therapeutics
Industry
Eligibility
18 Years to 59 Years
Enrollment
1,028 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
65
States / cities
Colorado Springs, Colorado • Denver, Colorado • Englewood, Colorado + 58 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2010 · Synced Oct 31, 2026, 11:12 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Dopamine Receptor Contributions to Prediction Error and Reversal Learning in Anorexia Nervosa

NCT04128683
View directory record Official record
Conditions
Anorexia Nervosa
Interventions
amisulpride, bromocriptine, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 29 Years · Female only
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 11, 2025 · Synced Oct 31, 2026, 11:12 PM EDT
Terminated Phase 2 Interventional Results available

Evaluation of FDY-5301 in Major Trauma Patients in ICU

NCT04430283
View directory record Official record
Conditions
ICU Acquired Weakness
Interventions
FDY-5301, Placebo
Drug · Other
Lead sponsor
Faraday Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
5
States / cities
Torrance, California • Gainesville, Florida • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2023 · Synced Oct 31, 2026, 11:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effects of Blackcurrant Supplementation on Eye Health

NCT04775654
View directory record Official record
Conditions
Eye Strain, Eye Fatigue
Interventions
Blackcurrant, Placebo
Dietary Supplement · Other
Lead sponsor
Nutraceuticals Research Institute
Other
Eligibility
30 Years to 60 Years · Female only
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Franklin, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 24, 2022 · Synced Oct 31, 2026, 11:12 PM EDT
Completed Phase 3 Interventional Results available

Bioequivalence Study of Two Treatments in the Treatment of Acne Vulgaris on the Face

NCT03393494
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Adapalene and Benzoyl Peroxide Topical Gel, Epiduo Topical Product, Placebo
Drug
Lead sponsor
Padagis LLC
Industry
Eligibility
12 Years to 40 Years
Enrollment
825 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Oct 31, 2026, 11:12 PM EDT
Completed Phase 3 Interventional Results available

Treatment of Erectile Dysfunction II

NCT01037218
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
Udenafil, Placebo
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
19 Years and older · Male only
Enrollment
601 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
40
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tempe, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2015 · Synced Oct 31, 2026, 11:12 PM EDT